nodes	percent_of_prediction	percent_of_DWPC	metapath
Travoprost—PTGFR—ciliary body—melanoma	0.373	0.903	CbGeAlD
Travoprost—PTGFR—eye—melanoma	0.0203	0.0491	CbGeAlD
Travoprost—PTGFR—head—melanoma	0.0115	0.0279	CbGeAlD
Travoprost—Conjunctival oedema—Carmustine—melanoma	0.0107	0.0269	CcSEcCtD
Travoprost—Hyperaemia—Carmustine—melanoma	0.00983	0.0247	CcSEcCtD
Travoprost—Retinal haemorrhage—Carmustine—melanoma	0.00911	0.0229	CcSEcCtD
Travoprost—Periorbital oedema—Bleomycin—melanoma	0.0086	0.0216	CcSEcCtD
Travoprost—PTGFR—lymph node—melanoma	0.00806	0.0195	CbGeAlD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—EDNRB—melanoma	0.00782	0.0413	CbGpPWpGaD
Travoprost—Photopsia—Docetaxel—melanoma	0.006	0.0151	CcSEcCtD
Travoprost—Skin hyperpigmentation—Bleomycin—melanoma	0.00572	0.0144	CcSEcCtD
Travoprost—Musculoskeletal pain—Vemurafenib—melanoma	0.00568	0.0143	CcSEcCtD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—EDN1—melanoma	0.00533	0.0281	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Other—CXCR1—melanoma	0.005	0.0264	CbGpPWpGaD
Travoprost—Skin hyperpigmentation—Carmustine—melanoma	0.00499	0.0126	CcSEcCtD
Travoprost—Visual acuity reduced—Temozolomide—melanoma	0.00482	0.0121	CcSEcCtD
Travoprost—PTGFR—GPCRs, Other—GRM1—melanoma	0.00472	0.0249	CbGpPWpGaD
Travoprost—Arthritis—Vemurafenib—melanoma	0.00419	0.0105	CcSEcCtD
Travoprost—PTGFR—GPCRs, Other—CXCR2—melanoma	0.00391	0.0207	CbGpPWpGaD
Travoprost—Scotoma—Carmustine—melanoma	0.00391	0.00983	CcSEcCtD
Travoprost—Tenderness—Bleomycin—melanoma	0.0039	0.00981	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—PLCB4—melanoma	0.00383	0.0202	CbGpPWpGaD
Travoprost—Scotoma—Temozolomide—melanoma	0.00378	0.0095	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PLCB4—melanoma	0.00342	0.0181	CbGpPWpGaD
Travoprost—Accidental injury—Carmustine—melanoma	0.00336	0.00844	CcSEcCtD
Travoprost—PTGFR—GPCRs, Other—F2R—melanoma	0.00332	0.0176	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—F2RL1—melanoma	0.00325	0.0172	CbGpPWpGaD
Travoprost—Lacrimation—Docetaxel—melanoma	0.00324	0.00816	CcSEcCtD
Travoprost—Skin hyperpigmentation—Docetaxel—melanoma	0.00321	0.00807	CcSEcCtD
Travoprost—Infestation NOS—Vemurafenib—melanoma	0.00314	0.0079	CcSEcCtD
Travoprost—Infestation—Vemurafenib—melanoma	0.00314	0.0079	CcSEcCtD
Travoprost—Herpes simplex—Temozolomide—melanoma	0.00311	0.00783	CcSEcCtD
Travoprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—melanoma	0.00297	0.0157	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—F2RL1—melanoma	0.00291	0.0154	CbGpPWpGaD
Travoprost—Musculoskeletal pain—Temozolomide—melanoma	0.0029	0.00731	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—KISS1—melanoma	0.0029	0.0153	CbGpPWpGaD
Travoprost—Urinary incontinence—Carmustine—melanoma	0.00287	0.00721	CcSEcCtD
Travoprost—Urinary incontinence—Temozolomide—melanoma	0.00277	0.00697	CcSEcCtD
Travoprost—Connective tissue disorder—Vemurafenib—melanoma	0.00277	0.00697	CcSEcCtD
Travoprost—Injury—Bleomycin—melanoma	0.00269	0.00676	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—GRM1—melanoma	0.00265	0.014	CbGpPWpGaD
Travoprost—Dry eye—Temozolomide—melanoma	0.00265	0.00667	CcSEcCtD
Travoprost—Eye disorder—Vemurafenib—melanoma	0.00263	0.00663	CcSEcCtD
Travoprost—Cardiac disorder—Vemurafenib—melanoma	0.00262	0.00658	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—melanoma	0.00259	0.0137	CbGpPWpGaD
Travoprost—Abnormal vision—Carmustine—melanoma	0.00259	0.00651	CcSEcCtD
Travoprost—Dermatitis atopic—Docetaxel—melanoma	0.00258	0.00648	CcSEcCtD
Travoprost—Angiopathy—Vemurafenib—melanoma	0.00256	0.00643	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—TAS2R60—melanoma	0.00255	0.0134	CbGpPWpGaD
Travoprost—Mediastinal disorder—Vemurafenib—melanoma	0.00254	0.00639	CcSEcCtD
Travoprost—Arthritis—Bleomycin—melanoma	0.00254	0.00639	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL1—melanoma	0.00253	0.0134	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—F2RL1—melanoma	0.00251	0.0133	CbGpPWpGaD
Travoprost—Scotoma—Docetaxel—melanoma	0.00251	0.00632	CcSEcCtD
Travoprost—Abnormal vision—Temozolomide—melanoma	0.0025	0.00629	CcSEcCtD
Travoprost—Erythema—Vemurafenib—melanoma	0.00245	0.00617	CcSEcCtD
Travoprost—Dysgeusia—Vemurafenib—melanoma	0.0024	0.00605	CcSEcCtD
Travoprost—Eye pain—Carmustine—melanoma	0.00239	0.00601	CcSEcCtD
Travoprost—Back pain—Vemurafenib—melanoma	0.00237	0.00597	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—melanoma	0.00237	0.0125	CbGpPWpGaD
Travoprost—Injury—Carmustine—melanoma	0.00234	0.0059	CcSEcCtD
Travoprost—Eye pain—Temozolomide—melanoma	0.00231	0.0058	CcSEcCtD
Travoprost—Nasal congestion—Temozolomide—melanoma	0.00229	0.00575	CcSEcCtD
Travoprost—Eye irritation—Docetaxel—melanoma	0.00223	0.00562	CcSEcCtD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CXCR1—melanoma	0.00217	0.0115	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—F2RL1—melanoma	0.00215	0.0114	CbGpPWpGaD
Travoprost—Cough—Vemurafenib—melanoma	0.00214	0.00539	CcSEcCtD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—MC1R—melanoma	0.00214	0.0113	CbGpPWpGaD
Travoprost—Bone disorder—Docetaxel—melanoma	0.00211	0.00531	CcSEcCtD
Travoprost—Oropharyngeal pain—Docetaxel—melanoma	0.0021	0.00528	CcSEcCtD
Travoprost—Myalgia—Vemurafenib—melanoma	0.00209	0.00526	CcSEcCtD
Travoprost—Arthralgia—Vemurafenib—melanoma	0.00209	0.00526	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00207	0.00522	CcSEcCtD
Travoprost—Lacrimation increased—Docetaxel—melanoma	0.00207	0.00521	CcSEcCtD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CCR7—melanoma	0.00205	0.0108	CbGpPWpGaD
Travoprost—Infection—Vemurafenib—melanoma	0.00199	0.00501	CcSEcCtD
Travoprost—Inflammation—Docetaxel—melanoma	0.00197	0.00495	CcSEcCtD
Travoprost—Nervous system disorder—Vemurafenib—melanoma	0.00196	0.00494	CcSEcCtD
Travoprost—Skin disorder—Vemurafenib—melanoma	0.00195	0.00489	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CXCL1—melanoma	0.00193	0.0102	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—KISS1—melanoma	0.00192	0.0101	CbGpPWpGaD
Travoprost—Blood pressure increased—Docetaxel—melanoma	0.00191	0.0048	CcSEcCtD
Travoprost—Hypotension—Vemurafenib—melanoma	0.00187	0.00471	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—F2R—melanoma	0.00187	0.00987	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCR1—melanoma	0.00186	0.00982	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—MC1R—melanoma	0.00183	0.00968	CbGpPWpGaD
Travoprost—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00182	0.00459	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—EDNRB—melanoma	0.00181	0.00956	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCR7—melanoma	0.00176	0.00928	CbGpPWpGaD
Travoprost—Bronchitis—Temozolomide—melanoma	0.00173	0.00435	CcSEcCtD
Travoprost—Gastrointestinal disorder—Vemurafenib—melanoma	0.00173	0.00435	CcSEcCtD
Travoprost—Fatigue—Vemurafenib—melanoma	0.00173	0.00434	CcSEcCtD
Travoprost—Constipation—Vemurafenib—melanoma	0.00171	0.00431	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—GNA11—melanoma	0.00171	0.00903	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CXCR2—melanoma	0.0017	0.00897	CbGpPWpGaD
Travoprost—Dysuria—Temozolomide—melanoma	0.00168	0.00423	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—melanoma	0.00167	0.00883	CbGpPWpGaD
Travoprost—Depression—Carmustine—melanoma	0.00166	0.00417	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—F2RL1—melanoma	0.00164	0.00867	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—melanoma	0.00162	0.00855	CbGpPWpGaD
Travoprost—Urinary tract infection—Carmustine—melanoma	0.00161	0.00406	CcSEcCtD
Travoprost—Infestation NOS—Temozolomide—melanoma	0.0016	0.00404	CcSEcCtD
Travoprost—Infestation—Temozolomide—melanoma	0.0016	0.00404	CcSEcCtD
Travoprost—Depression—Temozolomide—melanoma	0.0016	0.00403	CcSEcCtD
Travoprost—PTGFR—G alpha (q) signalling events—GNAQ—melanoma	0.00159	0.00839	CbGpPWpGaD
Travoprost—Pharyngitis—Dactinomycin—melanoma	0.00158	0.00398	CcSEcCtD
Travoprost—Urinary tract infection—Temozolomide—melanoma	0.00156	0.00392	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—GRM3—melanoma	0.00154	0.00815	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—melanoma	0.00153	0.00807	CbGpPWpGaD
Travoprost—Sinusitis—Temozolomide—melanoma	0.00151	0.00379	CcSEcCtD
Travoprost—Erythema—Bleomycin—melanoma	0.00149	0.00374	CcSEcCtD
Travoprost—Hypersensitivity—Vemurafenib—melanoma	0.00148	0.00371	CcSEcCtD
Travoprost—Connective tissue disorder—Carmustine—melanoma	0.00147	0.00369	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—KISS1—melanoma	0.00146	0.00772	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCR2—melanoma	0.00146	0.00769	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—F2R—melanoma	0.00144	0.00763	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—TAS2R60—melanoma	0.00144	0.0076	CbGpPWpGaD
Travoprost—Asthenia—Vemurafenib—melanoma	0.00144	0.00362	CcSEcCtD
Travoprost—Visual impairment—Carmustine—melanoma	0.00144	0.00361	CcSEcCtD
Travoprost—Pharyngitis—Temozolomide—melanoma	0.00143	0.0036	CcSEcCtD
Travoprost—Urinary tract disorder—Temozolomide—melanoma	0.00142	0.00358	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—melanoma	0.00142	0.00751	CbGpPWpGaD
Travoprost—Pruritus—Vemurafenib—melanoma	0.00142	0.00356	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CXCR1—melanoma	0.00142	0.00748	CbGpPWpGaD
Travoprost—Connective tissue disorder—Temozolomide—melanoma	0.00142	0.00356	CcSEcCtD
Travoprost—Urethral disorder—Temozolomide—melanoma	0.00141	0.00355	CcSEcCtD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—EDNRB—melanoma	0.0014	0.00739	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—MC1R—melanoma	0.0014	0.00737	CbGpPWpGaD
Travoprost—Eye disorder—Carmustine—melanoma	0.00139	0.00351	CcSEcCtD
Travoprost—Visual impairment—Temozolomide—melanoma	0.00139	0.00349	CcSEcCtD
Travoprost—Erythema—Dactinomycin—melanoma	0.00139	0.00349	CcSEcCtD
Travoprost—Ill-defined disorder—Bleomycin—melanoma	0.00138	0.00347	CcSEcCtD
Travoprost—Diarrhoea—Vemurafenib—melanoma	0.00137	0.00345	CcSEcCtD
Travoprost—Eye disorder—Temozolomide—melanoma	0.00135	0.00339	CcSEcCtD
Travoprost—Tinnitus—Temozolomide—melanoma	0.00134	0.00338	CcSEcCtD
Travoprost—Malaise—Bleomycin—melanoma	0.00134	0.00337	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CCR7—melanoma	0.00134	0.00706	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—GRM1—melanoma	0.00134	0.00706	CbGpPWpGaD
Travoprost—Cardiac disorder—Temozolomide—melanoma	0.00134	0.00336	CcSEcCtD
Travoprost—Dizziness—Vemurafenib—melanoma	0.00132	0.00333	CcSEcCtD
Travoprost—Angiopathy—Temozolomide—melanoma	0.00131	0.00329	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—TAS2R60—melanoma	0.00131	0.0069	CbGpPWpGaD
Travoprost—Mental disorder—Carmustine—melanoma	0.00131	0.00329	CcSEcCtD
Travoprost—Immune system disorder—Temozolomide—melanoma	0.0013	0.00327	CcSEcCtD
Travoprost—Mediastinal disorder—Temozolomide—melanoma	0.0013	0.00327	CcSEcCtD
Travoprost—Erythema—Carmustine—melanoma	0.0013	0.00326	CcSEcCtD
Travoprost—Cough—Bleomycin—melanoma	0.0013	0.00326	CcSEcCtD
Travoprost—Ill-defined disorder—Dactinomycin—melanoma	0.00129	0.00324	CcSEcCtD
Travoprost—Chest pain—Bleomycin—melanoma	0.00127	0.00318	CcSEcCtD
Travoprost—Myalgia—Bleomycin—melanoma	0.00127	0.00318	CcSEcCtD
Travoprost—Rash—Vemurafenib—melanoma	0.00126	0.00318	CcSEcCtD
Travoprost—Mental disorder—Temozolomide—melanoma	0.00126	0.00318	CcSEcCtD
Travoprost—Dermatitis—Vemurafenib—melanoma	0.00126	0.00317	CcSEcCtD
Travoprost—Back pain—Carmustine—melanoma	0.00126	0.00316	CcSEcCtD
Travoprost—Headache—Vemurafenib—melanoma	0.00125	0.00316	CcSEcCtD
Travoprost—Erythema—Temozolomide—melanoma	0.00125	0.00316	CcSEcCtD
Travoprost—Discomfort—Bleomycin—melanoma	0.00125	0.00315	CcSEcCtD
Travoprost—Malaise—Dactinomycin—melanoma	0.00125	0.00315	CcSEcCtD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CXCR4—melanoma	0.00124	0.00656	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—F2R—melanoma	0.00124	0.00654	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—EDN1—melanoma	0.00123	0.00651	CbGpPWpGaD
Travoprost—Dysgeusia—Temozolomide—melanoma	0.00123	0.00309	CcSEcCtD
Travoprost—Vision blurred—Carmustine—melanoma	0.00122	0.00308	CcSEcCtD
Travoprost—Oedema—Bleomycin—melanoma	0.00121	0.00305	CcSEcCtD
Travoprost—Back pain—Temozolomide—melanoma	0.00121	0.00305	CcSEcCtD
Travoprost—Infection—Bleomycin—melanoma	0.00121	0.00303	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—EDNRB—melanoma	0.0012	0.00633	CbGpPWpGaD
Travoprost—Nausea—Vemurafenib—melanoma	0.00119	0.00299	CcSEcCtD
Travoprost—Vision blurred—Temozolomide—melanoma	0.00118	0.00297	CcSEcCtD
Travoprost—Myalgia—Dactinomycin—melanoma	0.00118	0.00297	CcSEcCtD
Travoprost—Discomfort—Dactinomycin—melanoma	0.00117	0.00293	CcSEcCtD
Travoprost—Angina pectoris—Docetaxel—melanoma	0.00117	0.00293	CcSEcCtD
Travoprost—Ill-defined disorder—Temozolomide—melanoma	0.00116	0.00293	CcSEcCtD
Travoprost—Hypotension—Bleomycin—melanoma	0.00113	0.00285	CcSEcCtD
Travoprost—Oedema—Dactinomycin—melanoma	0.00113	0.00285	CcSEcCtD
Travoprost—Malaise—Temozolomide—melanoma	0.00113	0.00285	CcSEcCtD
Travoprost—Vertigo—Temozolomide—melanoma	0.00113	0.00283	CcSEcCtD
Travoprost—Infection—Dactinomycin—melanoma	0.00112	0.00283	CcSEcCtD
Travoprost—Hypertension—Carmustine—melanoma	0.00112	0.00282	CcSEcCtD
Travoprost—Palpitations—Temozolomide—melanoma	0.00111	0.00279	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CXCR2—melanoma	0.00111	0.00585	CbGpPWpGaD
Travoprost—Musculoskeletal discomfort—Bleomycin—melanoma	0.00111	0.00278	CcSEcCtD
Travoprost—Chest pain—Carmustine—melanoma	0.0011	0.00278	CcSEcCtD
Travoprost—Myalgia—Carmustine—melanoma	0.0011	0.00278	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—melanoma	0.0011	0.00582	CbGpPWpGaD
Travoprost—Anxiety—Carmustine—melanoma	0.0011	0.00277	CcSEcCtD
Travoprost—Cough—Temozolomide—melanoma	0.00109	0.00275	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—CXCL1—melanoma	0.00109	0.00576	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PLCB4—melanoma	0.00109	0.00576	CbGpPWpGaD
Travoprost—Hypertension—Temozolomide—melanoma	0.00108	0.00272	CcSEcCtD
Travoprost—Dyspnoea—Bleomycin—melanoma	0.00108	0.00272	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—WNT5A—melanoma	0.00107	0.00567	CbGpPWpGaD
Travoprost—Arthralgia—Temozolomide—melanoma	0.00107	0.00269	CcSEcCtD
Travoprost—Myalgia—Temozolomide—melanoma	0.00107	0.00269	CcSEcCtD
Travoprost—Infestation—Docetaxel—melanoma	0.00107	0.00268	CcSEcCtD
Travoprost—Infestation NOS—Docetaxel—melanoma	0.00107	0.00268	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCR4—melanoma	0.00106	0.00562	CbGpPWpGaD
Travoprost—Anxiety—Temozolomide—melanoma	0.00106	0.00268	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00106	0.00267	CcSEcCtD
Travoprost—Oedema—Carmustine—melanoma	0.00106	0.00266	CcSEcCtD
Travoprost—Discomfort—Temozolomide—melanoma	0.00105	0.00265	CcSEcCtD
Travoprost—Infection—Carmustine—melanoma	0.00105	0.00265	CcSEcCtD
Travoprost—Dry mouth—Temozolomide—melanoma	0.00104	0.00263	CcSEcCtD
Travoprost—Pain—Bleomycin—melanoma	0.00104	0.00261	CcSEcCtD
Travoprost—Conjunctivitis—Docetaxel—melanoma	0.00104	0.00261	CcSEcCtD
Travoprost—Tachycardia—Carmustine—melanoma	0.00103	0.0026	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCA—melanoma	0.00103	0.00545	CbGpPWpGaD
Travoprost—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00103	0.00259	CcSEcCtD
Travoprost—Oedema—Temozolomide—melanoma	0.00102	0.00258	CcSEcCtD
Travoprost—Infection—Temozolomide—melanoma	0.00102	0.00256	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K2—melanoma	0.00101	0.00533	CbGpPWpGaD
Travoprost—Nervous system disorder—Temozolomide—melanoma	0.001	0.00253	CcSEcCtD
Travoprost—Feeling abnormal—Bleomycin—melanoma	0.001	0.00252	CcSEcCtD
Travoprost—Skin disorder—Temozolomide—melanoma	0.000994	0.0025	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—PLCB4—melanoma	0.00099	0.00523	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCL1—melanoma	0.00099	0.00523	CbGpPWpGaD
Travoprost—Hypotension—Carmustine—melanoma	0.00099	0.00249	CcSEcCtD
Travoprost—Fatigue—Dactinomycin—melanoma	0.000976	0.00245	CcSEcCtD
Travoprost—Pain—Dactinomycin—melanoma	0.000968	0.00243	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Carmustine—melanoma	0.000965	0.00243	CcSEcCtD
Travoprost—Rhinitis—Docetaxel—melanoma	0.000961	0.00242	CcSEcCtD
Travoprost—Pharyngitis—Docetaxel—melanoma	0.000951	0.00239	CcSEcCtD
Travoprost—Urinary tract disorder—Docetaxel—melanoma	0.000946	0.00238	CcSEcCtD
Travoprost—Dyspnoea—Carmustine—melanoma	0.000944	0.00238	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—F2R—melanoma	0.000942	0.00498	CbGpPWpGaD
Travoprost—Connective tissue disorder—Docetaxel—melanoma	0.000942	0.00237	CcSEcCtD
Travoprost—Urethral disorder—Docetaxel—melanoma	0.000939	0.00236	CcSEcCtD
Travoprost—Feeling abnormal—Dactinomycin—melanoma	0.000933	0.00235	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Temozolomide—melanoma	0.000933	0.00235	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—F2RL1—melanoma	0.000927	0.0049	CbGpPWpGaD
Travoprost—Gastrointestinal pain—Dactinomycin—melanoma	0.000925	0.00233	CcSEcCtD
Travoprost—Visual impairment—Docetaxel—melanoma	0.000923	0.00232	CcSEcCtD
Travoprost—Gastrointestinal disorder—Carmustine—melanoma	0.000914	0.0023	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—EDNRB—melanoma	0.000913	0.00482	CbGpPWpGaD
Travoprost—Dyspnoea—Temozolomide—melanoma	0.000913	0.0023	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—MYO7A—melanoma	0.000908	0.00479	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—DRAP1—melanoma	0.000908	0.00479	CbGpPWpGaD
Travoprost—Pain—Carmustine—melanoma	0.000906	0.00228	CcSEcCtD
Travoprost—Constipation—Carmustine—melanoma	0.000906	0.00228	CcSEcCtD
Travoprost—Dyspepsia—Temozolomide—melanoma	0.000901	0.00227	CcSEcCtD
Travoprost—Eye disorder—Docetaxel—melanoma	0.000895	0.00225	CcSEcCtD
Travoprost—Abdominal pain—Dactinomycin—melanoma	0.000895	0.00225	CcSEcCtD
Travoprost—Hypersensitivity—Bleomycin—melanoma	0.000894	0.00225	CcSEcCtD
Travoprost—Cardiac disorder—Docetaxel—melanoma	0.000889	0.00224	CcSEcCtD
Travoprost—Gastrointestinal disorder—Temozolomide—melanoma	0.000884	0.00222	CcSEcCtD
Travoprost—Fatigue—Temozolomide—melanoma	0.000882	0.00222	CcSEcCtD
Travoprost—Pain—Temozolomide—melanoma	0.000875	0.0022	CcSEcCtD
Travoprost—Constipation—Temozolomide—melanoma	0.000875	0.0022	CcSEcCtD
Travoprost—Feeling abnormal—Carmustine—melanoma	0.000873	0.0022	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—GRM3—melanoma	0.000872	0.0046	CbGpPWpGaD
Travoprost—Asthenia—Bleomycin—melanoma	0.000871	0.00219	CcSEcCtD
Travoprost—Angiopathy—Docetaxel—melanoma	0.000869	0.00219	CcSEcCtD
Travoprost—Gastrointestinal pain—Carmustine—melanoma	0.000866	0.00218	CcSEcCtD
Travoprost—Immune system disorder—Docetaxel—melanoma	0.000865	0.00218	CcSEcCtD
Travoprost—Mediastinal disorder—Docetaxel—melanoma	0.000863	0.00217	CcSEcCtD
Travoprost—Pruritus—Bleomycin—melanoma	0.000859	0.00216	CcSEcCtD
Travoprost—Feeling abnormal—Temozolomide—melanoma	0.000843	0.00212	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—F2RL1—melanoma	0.000842	0.00445	CbGpPWpGaD
Travoprost—Mental disorder—Docetaxel—melanoma	0.000839	0.00211	CcSEcCtD
Travoprost—Abdominal pain—Carmustine—melanoma	0.000837	0.00211	CcSEcCtD
Travoprost—Gastrointestinal pain—Temozolomide—melanoma	0.000837	0.00211	CcSEcCtD
Travoprost—Erythema—Docetaxel—melanoma	0.000834	0.0021	CcSEcCtD
Travoprost—Hypersensitivity—Dactinomycin—melanoma	0.000834	0.0021	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—KISS1—melanoma	0.000826	0.00437	CbGpPWpGaD
Travoprost—Dysgeusia—Docetaxel—melanoma	0.000817	0.00205	CcSEcCtD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—EDN1—melanoma	0.000816	0.00431	CbGpPWpGaD
Travoprost—Asthenia—Dactinomycin—melanoma	0.000812	0.00204	CcSEcCtD
Travoprost—PTGFR—GPCR ligand binding—CXCR4—melanoma	0.00081	0.00428	CbGpPWpGaD
Travoprost—Abdominal pain—Temozolomide—melanoma	0.000809	0.00204	CcSEcCtD
Travoprost—Back pain—Docetaxel—melanoma	0.000807	0.00203	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—CXCR1—melanoma	0.0008	0.00423	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GRM3—melanoma	0.000792	0.00418	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—MC1R—melanoma	0.000788	0.00416	CbGpPWpGaD
Travoprost—Hypersensitivity—Carmustine—melanoma	0.00078	0.00196	CcSEcCtD
Travoprost—Diarrhoea—Dactinomycin—melanoma	0.000774	0.00195	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—TAS2R60—melanoma	0.000772	0.00408	CbGpPWpGaD
Travoprost—Rash—Bleomycin—melanoma	0.000765	0.00192	CcSEcCtD
Travoprost—Dermatitis—Bleomycin—melanoma	0.000764	0.00192	CcSEcCtD
Travoprost—Asthenia—Carmustine—melanoma	0.00076	0.00191	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—GRM1—melanoma	0.000756	0.00399	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CCR7—melanoma	0.000756	0.00399	CbGpPWpGaD
Travoprost—Hypersensitivity—Temozolomide—melanoma	0.000754	0.0019	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—KISS1—melanoma	0.000751	0.00396	CbGpPWpGaD
Travoprost—Palpitations—Docetaxel—melanoma	0.000737	0.00185	CcSEcCtD
Travoprost—Asthenia—Temozolomide—melanoma	0.000734	0.00185	CcSEcCtD
Travoprost—Cough—Docetaxel—melanoma	0.000728	0.00183	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—CXCR1—melanoma	0.000727	0.00384	CbGpPWpGaD
Travoprost—Diarrhoea—Carmustine—melanoma	0.000725	0.00182	CcSEcCtD
Travoprost—Pruritus—Temozolomide—melanoma	0.000724	0.00182	CcSEcCtD
Travoprost—Nausea—Bleomycin—melanoma	0.000721	0.00181	CcSEcCtD
Travoprost—Hypertension—Docetaxel—melanoma	0.00072	0.00181	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—MC1R—melanoma	0.000716	0.00378	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—melanoma	0.000716	0.00378	CbGpPWpGaD
Travoprost—Rash—Dactinomycin—melanoma	0.000714	0.0018	CcSEcCtD
Travoprost—Arthralgia—Docetaxel—melanoma	0.00071	0.00179	CcSEcCtD
Travoprost—Chest pain—Docetaxel—melanoma	0.00071	0.00179	CcSEcCtD
Travoprost—Myalgia—Docetaxel—melanoma	0.00071	0.00179	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000705	0.00177	CcSEcCtD
Travoprost—Dizziness—Carmustine—melanoma	0.0007	0.00176	CcSEcCtD
Travoprost—Diarrhoea—Temozolomide—melanoma	0.0007	0.00176	CcSEcCtD
Travoprost—Dry mouth—Docetaxel—melanoma	0.000694	0.00175	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—RHOB—melanoma	0.000688	0.00363	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GRM1—melanoma	0.000686	0.00363	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCR7—melanoma	0.000686	0.00363	CbGpPWpGaD
Travoprost—Oedema—Docetaxel—melanoma	0.000681	0.00171	CcSEcCtD
Travoprost—Dizziness—Temozolomide—melanoma	0.000677	0.0017	CcSEcCtD
Travoprost—Infection—Docetaxel—melanoma	0.000676	0.0017	CcSEcCtD
Travoprost—Nausea—Dactinomycin—melanoma	0.000672	0.00169	CcSEcCtD
Travoprost—Rash—Carmustine—melanoma	0.000668	0.00168	CcSEcCtD
Travoprost—Nervous system disorder—Docetaxel—melanoma	0.000668	0.00168	CcSEcCtD
Travoprost—Dermatitis—Carmustine—melanoma	0.000667	0.00168	CcSEcCtD
Travoprost—Tachycardia—Docetaxel—melanoma	0.000664	0.00167	CcSEcCtD
Travoprost—Headache—Carmustine—melanoma	0.000664	0.00167	CcSEcCtD
Travoprost—Skin disorder—Docetaxel—melanoma	0.000661	0.00166	CcSEcCtD
Travoprost—Rash—Temozolomide—melanoma	0.000645	0.00162	CcSEcCtD
Travoprost—Dermatitis—Temozolomide—melanoma	0.000645	0.00162	CcSEcCtD
Travoprost—Headache—Temozolomide—melanoma	0.000641	0.00161	CcSEcCtD
Travoprost—Hypotension—Docetaxel—melanoma	0.000636	0.0016	CcSEcCtD
Travoprost—Nausea—Carmustine—melanoma	0.000629	0.00158	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—CXCR2—melanoma	0.000626	0.00331	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—RHOB—melanoma	0.000624	0.0033	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—EDN1—melanoma	0.000621	0.00328	CbGpPWpGaD
Travoprost—Musculoskeletal discomfort—Docetaxel—melanoma	0.00062	0.00156	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—RAC2—melanoma	0.000616	0.00325	CbGpPWpGaD
Travoprost—Nausea—Temozolomide—melanoma	0.000608	0.00153	CcSEcCtD
Travoprost—Dyspnoea—Docetaxel—melanoma	0.000607	0.00153	CcSEcCtD
Travoprost—Dyspepsia—Docetaxel—melanoma	0.000599	0.00151	CcSEcCtD
Travoprost—Gastrointestinal disorder—Docetaxel—melanoma	0.000588	0.00148	CcSEcCtD
Travoprost—Fatigue—Docetaxel—melanoma	0.000587	0.00148	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PLCB4—melanoma	0.000585	0.00309	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCL1—melanoma	0.000585	0.00309	CbGpPWpGaD
Travoprost—Constipation—Docetaxel—melanoma	0.000582	0.00146	CcSEcCtD
Travoprost—Pain—Docetaxel—melanoma	0.000582	0.00146	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—CXCR2—melanoma	0.000569	0.003	CbGpPWpGaD
Travoprost—Feeling abnormal—Docetaxel—melanoma	0.000561	0.00141	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—RAC2—melanoma	0.00056	0.00296	CbGpPWpGaD
Travoprost—Gastrointestinal pain—Docetaxel—melanoma	0.000557	0.0014	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—WNT5A—melanoma	0.000551	0.00291	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TRRAP—melanoma	0.00055	0.00291	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CUL3—melanoma	0.00055	0.00291	CbGpPWpGaD
Travoprost—Abdominal pain—Docetaxel—melanoma	0.000538	0.00135	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—AKR1B10—melanoma	0.000535	0.00283	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—F2R—melanoma	0.000533	0.00281	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—EDNRB—melanoma	0.000516	0.00272	CbGpPWpGaD
Travoprost—Hypersensitivity—Docetaxel—melanoma	0.000502	0.00126	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—F2RL1—melanoma	0.000497	0.00263	CbGpPWpGaD
Travoprost—Asthenia—Docetaxel—melanoma	0.000488	0.00123	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—GAB2—melanoma	0.000487	0.00257	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—GNA11—melanoma	0.000487	0.00257	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—F2R—melanoma	0.000484	0.00255	CbGpPWpGaD
Travoprost—Pruritus—Docetaxel—melanoma	0.000482	0.00121	CcSEcCtD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—melanoma	0.000478	0.00252	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—EDNRB—melanoma	0.000468	0.00247	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GRM3—melanoma	0.000468	0.00247	CbGpPWpGaD
Travoprost—Diarrhoea—Docetaxel—melanoma	0.000466	0.00117	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—CXCR4—melanoma	0.000458	0.00242	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—melanoma	0.000458	0.00242	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—GNAQ—melanoma	0.000453	0.00239	CbGpPWpGaD
Travoprost—Dizziness—Docetaxel—melanoma	0.00045	0.00113	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—KISS1—melanoma	0.000443	0.00234	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GNA11—melanoma	0.000442	0.00234	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GAB2—melanoma	0.000442	0.00234	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000441	0.00233	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—melanoma	0.000435	0.0023	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—melanoma	0.000435	0.0023	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SKI—melanoma	0.000429	0.00227	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCR1—melanoma	0.000429	0.00227	CbGpPWpGaD
Travoprost—Rash—Docetaxel—melanoma	0.000429	0.00108	CcSEcCtD
Travoprost—Dermatitis—Docetaxel—melanoma	0.000429	0.00108	CcSEcCtD
Travoprost—Headache—Docetaxel—melanoma	0.000426	0.00107	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—MC1R—melanoma	0.000423	0.00223	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—PIK3CA—melanoma	0.000422	0.00223	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—AKT3—melanoma	0.000418	0.00221	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCR4—melanoma	0.000416	0.0022	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GNAQ—melanoma	0.000411	0.00217	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—melanoma	0.000411	0.00217	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GRM1—melanoma	0.000405	0.00214	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCR7—melanoma	0.000405	0.00214	CbGpPWpGaD
Travoprost—Nausea—Docetaxel—melanoma	0.000404	0.00102	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—SUFU—melanoma	0.000395	0.00209	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AKT3—melanoma	0.000379	0.002	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—melanoma	0.000378	0.002	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RHOB—melanoma	0.000369	0.00195	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—BCL2L11—melanoma	0.000369	0.00195	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HDAC6—melanoma	0.000354	0.00187	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—EDN1—melanoma	0.000351	0.00185	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—melanoma	0.00035	0.00185	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CSF2—melanoma	0.000343	0.00181	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCR2—melanoma	0.000336	0.00177	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CXCL8—melanoma	0.000336	0.00177	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—melanoma	0.000335	0.00177	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RAC2—melanoma	0.000331	0.00175	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PRKCA—melanoma	0.000329	0.00174	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—WNT5A—melanoma	0.000325	0.00172	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VEGFC—melanoma	0.000325	0.00172	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—EDN1—melanoma	0.000319	0.00168	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CSF2—melanoma	0.000312	0.00165	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—RAC1—melanoma	0.000305	0.00161	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PRKCA—melanoma	0.000299	0.00158	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—MAP2K2—melanoma	0.000292	0.00154	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—F2R—melanoma	0.000286	0.00151	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—RAC1—melanoma	0.000277	0.00146	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EDNRB—melanoma	0.000277	0.00146	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PTK2B—melanoma	0.000269	0.00142	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GNA11—melanoma	0.000261	0.00138	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GAB2—melanoma	0.000261	0.00138	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FLT1—melanoma	0.00026	0.00137	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CG—melanoma	0.000258	0.00136	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FOXO4—melanoma	0.000246	0.0013	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HDAC2—melanoma	0.000246	0.0013	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCR4—melanoma	0.000246	0.0013	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GNAQ—melanoma	0.000243	0.00128	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CG—melanoma	0.000234	0.00124	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SYK—melanoma	0.000228	0.00121	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CD—melanoma	0.000227	0.0012	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ITGAV—melanoma	0.000224	0.00118	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AKT3—melanoma	0.000224	0.00118	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NGFR—melanoma	0.000224	0.00118	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SOCS1—melanoma	0.000208	0.0011	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—MAP2K1—melanoma	0.000207	0.00109	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—S100B—melanoma	0.000207	0.00109	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CD—melanoma	0.000206	0.00109	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ERBB4—melanoma	0.000198	0.00105	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CB—melanoma	0.000197	0.00104	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDKN2B—melanoma	0.000196	0.00104	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CD86—melanoma	0.00019	0.001	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCL8—melanoma	0.00019	0.001	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EDN1—melanoma	0.000188	0.000995	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CSF2—melanoma	0.000184	0.000972	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FGF1—melanoma	0.000184	0.000972	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—IL2—melanoma	0.000181	0.000958	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—E2F1—melanoma	0.00018	0.000952	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CB—melanoma	0.000179	0.000947	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PDGFRA—melanoma	0.000178	0.000942	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ITGB3—melanoma	0.000176	0.000932	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PRKCA—melanoma	0.000176	0.000932	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SPP1—melanoma	0.000173	0.000914	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAP2K2—melanoma	0.000173	0.000911	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCL8—melanoma	0.000172	0.00091	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL2—melanoma	0.000165	0.00087	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TERT—melanoma	0.000164	0.000867	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RAC1—melanoma	0.000164	0.000864	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HIF1A—melanoma	0.000157	0.000829	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KDR—melanoma	0.00015	0.000793	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FN1—melanoma	0.000144	0.000763	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NOTCH1—melanoma	0.000141	0.000747	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CD80—melanoma	0.000138	0.000732	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KIT—melanoma	0.000138	0.00073	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—APC—melanoma	0.000138	0.00073	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CG—melanoma	0.000138	0.00073	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—NRAS—melanoma	0.000138	0.00073	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EGF—melanoma	0.000137	0.000722	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—MAPK3—melanoma	0.000132	0.000699	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—BRAF—melanoma	0.00013	0.000686	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IGF1—melanoma	0.000127	0.000669	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—MAPK1—melanoma	0.000126	0.000665	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—EGFR—melanoma	0.000126	0.000665	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAP2K1—melanoma	0.000122	0.000646	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CD—melanoma	0.000122	0.000642	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CA—melanoma	0.00012	0.000636	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—KRAS—melanoma	0.000119	0.000628	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FGF2—melanoma	0.000116	0.000615	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PIK3CA—melanoma	0.000109	0.000577	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MDM2—melanoma	0.000109	0.000575	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ERBB2—melanoma	0.000107	0.000567	CbGpPWpGaD
Travoprost—Tafluprost—PTGS2—melanoma	0.000107	1	CrCbGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CB—melanoma	0.000106	0.00056	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCL8—melanoma	0.000102	0.000538	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—HRAS—melanoma	0.000101	0.000534	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDKN1B—melanoma	9.94e-05	0.000525	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—AKT1—melanoma	9.83e-05	0.000519	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CASP3—melanoma	9.74e-05	0.000515	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL2—melanoma	9.73e-05	0.000514	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL6—melanoma	9.68e-05	0.000511	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCND1—melanoma	9.48e-05	0.000501	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CTNNB1—melanoma	9.39e-05	0.000496	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MMP9—melanoma	9.21e-05	0.000486	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDKN1A—melanoma	9.17e-05	0.000485	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PTEN—melanoma	9.15e-05	0.000483	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NFKB1—melanoma	9.11e-05	0.000481	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AKT1—melanoma	8.93e-05	0.000472	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VEGFA—melanoma	8.27e-05	0.000437	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—STAT3—melanoma	8.19e-05	0.000432	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NRAS—melanoma	8.17e-05	0.000431	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAPK3—melanoma	7.82e-05	0.000413	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MYC—melanoma	7.61e-05	0.000402	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAPK1—melanoma	7.44e-05	0.000393	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EGFR—melanoma	7.44e-05	0.000393	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KRAS—melanoma	7.03e-05	0.000371	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CA—melanoma	6.46e-05	0.000341	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TP53—melanoma	6.25e-05	0.00033	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HRAS—melanoma	5.97e-05	0.000316	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL6—melanoma	5.72e-05	0.000302	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AKT1—melanoma	5.28e-05	0.000279	CbGpPWpGaD
